Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of MaxCyte Inc (NASDAQ: MXCT) closed at $1.61 in the last session, up 0.62% from day before closing price of $1.6. In other words, the price has increased by $0.62 from its previous closing price. On the day, 0.63 million shares were traded. MXCT stock price reached its highest trading level at $1.63 during the session, while it also had its lowest trading level at $1.57.
Ratios:
We take a closer look at MXCT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 11.71 and its Current Ratio is at 12.39. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
On July 22, 2025, Stephens started tracking the stock assigning a Overweight rating and target price of $6.Stephens initiated its Overweight rating on July 22, 2025, with a $6 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 25 ’25 when Hemrajani Rekha sold 10,684 shares for $2.09 per share. The transaction valued at 22,378 led to the insider holds 39,893 shares of the business.
Swirsky Douglas J bought 50,000 shares of MXCT for $64,500 on Aug 13 ’25. The CHIEF FINANCIAL OFFICER now owns 161,811 shares after completing the transaction at $1.29 per share. On Aug 13 ’25, another insider, Masoud Maher, who serves as the President and CEO of the company, bought 75,000 shares for $1.37 each. As a result, the insider paid 102,915 and bolstered with 175,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MXCT now has a Market Capitalization of 171636704 and an Enterprise Value of 63581704. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.80 while its Price-to-Book (P/B) ratio in mrq is 0.90. Its current Enterprise Value per Revenue stands at 1.778 whereas that against EBITDA is -1.293.
Stock Price History:
Over the past 52 weeks, MXCT has reached a high of $5.20, while it has fallen to a 52-week low of $1.26. The 50-Day Moving Average of the stock is 1.46%, while the 200-Day Moving Average is calculated to be -41.59%.
Shares Statistics:
According to the various share statistics, MXCT traded on average about 810.54K shares per day over the past 3-months and 1102450 shares per day over the past 10 days. A total of 106.59M shares are outstanding, with a floating share count of 97.60M. Insiders hold about 8.45% of the company’s shares, while institutions hold 68.03% stake in the company. Shares short for MXCT as of 1757894400 were 3549715 with a Short Ratio of 4.38, compared to 1755216000 on 3605346. Therefore, it implies a Short% of Shares Outstanding of 3549715 and a Short% of Float of 3.35.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate. The current performance of MaxCyte Inc (MXCT) in the stock market.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.08 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.36 and -$0.46 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.4, with 6.0 analysts recommending between -$0.33 and -$0.47.
Revenue Estimates
According to 6 analysts,. The current quarter’s revenue is expected to be $8.37M. It ranges from a high estimate of $9M to a low estimate of $7.61M. As of. The current estimate, MaxCyte Inc’s year-ago sales were $8.16MFor the next quarter, 6 analysts are estimating revenue of $9.03M. There is a high estimate of $9.5M for the next quarter, whereas the lowest estimate is $8.06M.
A total of 7 analysts have provided revenue estimates for MXCT’s current fiscal year. The highest revenue estimate was $37.4M, while the lowest revenue estimate was $34.57M, resulting in an average revenue estimate of $36.4M. In the same quarter a year ago, actual revenue was $38.63MBased on 7 analysts’ estimates, the company’s revenue will be $41.79M in the next fiscal year. The high estimate is $44.66M and the low estimate is $39.66M.
